Pharvaris’ (PHVS) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Pharvaris (NASDAQ:PHVS) in a report published on Tuesday morning, Marketbeat.com reports. The brokerage currently has a $42.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Royal Bank Of Canada boosted their price target on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Wells Fargo & Company started coverage on Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Friday, August 14th. Guggenheim boosted their target price on Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $59.50.

Pharvaris Stock Performance

NASDAQ PHVS opened at $37.51 on Tuesday. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -12.30 and a beta of -2.33. The firm has a 50 day simple moving average of $35.01 and a 200-day simple moving average of $31.34. Pharvaris has a one year low of $20.65 and a one year high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts predict that Pharvaris will post -3.1 EPS for the current fiscal year.

Insider Activity

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the sale, the insider directly owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. This represents a 24.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the sale, the chief executive officer owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 133,655 shares of company stock worth $4,798,202. Insiders own 11.84% of the company’s stock.

Hedge Funds Weigh In On Pharvaris

Several large investors have recently bought and sold shares of PHVS. Quantbot Technologies LP purchased a new stake in Pharvaris during the 2nd quarter worth about $41,000. JPMorgan Chase & Co. increased its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. Barclays PLC acquired a new stake in shares of Pharvaris during the 4th quarter worth about $77,000. CoreCap Advisors LLC acquired a new stake in shares of Pharvaris during the 2nd quarter worth about $93,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Pharvaris during the fourth quarter worth approximately $139,000.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Analysts continued to support Pharvaris after positive Phase 3 data for extended-release deucrictibant in the CHAPTER-3 prophylaxis trial. The drug met its primary and secondary efficacy endpoints, strengthening the case for regulatory filings expected to begin in the first half of 2027.
• Positive Sentiment: RBC Capital reaffirmed its Buy/Outperform view and raised its price target to $62 from $52, citing the potential for deucrictibant XR to capture share in the hereditary angioedema market. RBC Capital rating
• Positive Sentiment: Citizens JMP increased its target to $79 from $75 and maintained a Market Outperform rating. HC Wainwright reiterated Buy with a $60 target, while Wedbush maintained Outperform. These actions reflect growing analyst confidence following Pharvaris’ Phase 3 progress.
• Positive Sentiment: Commentary highlighted Pharvaris’ potential to offer oral therapies for both on-demand treatment and prevention of hereditary angioedema attacks, which could improve its competitive positioning. Pharvaris HAE market opportunity
• Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition in the HAE market. Pharvaris is still a clinical-stage biotechnology company, and RBC continues to classify the stock as speculative.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest sentiment overhang, although it does not alter the company’s clinical results.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.